New Class of Drugs Set to Treat Alzheimer’s, Parkinson’s
And Other Neurodegenerative Diseases
Also Appears Effective for Chronic Pain
Research from Brain Health Therapeutics has uncovered a remarkably effective combination of two FDA approved drugs.
The first plant-based drug slows the production of beta amyloid proteins thought to be a key contributor to the progression of Alzheimer’s disease. It has shown success in treating:
- Neurodegenerative diseases: Alzheimer’s (AD), Parkinson’s (PD),
- multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS)
- Traumatic brain injury
- Chronic pain
However, this drug has significant drawbacks — impairments in long term cognitive function and synaptic plasticity. This has limited both the dosage and the use of the drug.
Careful research now shows that combining the plant-based drug with another inexpensive and common class of drugs stops the decrease in memory, cognitive abilities, and concentration.
It allows the plant-based drug to work effectively while reducing or eliminating the negative side effects. This brings a new, potent treatment to neurodegenerative diseases and pain. It has the potential to address a host of other hard-to-treat diseases including: nausea from cancer treatments, PTSD, gastrointestinal ailments, migraine headaches, arthritis, asthma, and fibromyalgia.